NewsBenzingaB of A SecuritiesはKrystal Biotechに対する買いを維持し、価格目標を$400に引き上げました。 B of A SecuritiesはKrystal Biotechに対する買いを維持し、価格目標を$400に引き上げました。 Benzinga 2026.09.21 17:41 (GMT+0) Open on Benzinga Other news If Apple Cuts iPhone Units in 2027, This Stock Could Be a Big Loser Trust company AnchorWatch Trust Company launches Bitcoin custody service Wells Fargo Maintains Equal-Weight on PENN Entertainment, Lowers Price Target to $22 HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $85 Price Target Alphabet Stock Rises: What's Going On? $1000 Invested In Agilent Technologies 10 Years Ago Would Be Worth This Much Today
